Gene-editing has become one of the top investing buzzwords.
All as gene editing show progress in identifying and potentially curing diseases.
Plus, according to Ark Investment Management CEO Cathie Wood said, “I would have to say the biggest upside surprises are going to come from the genomic space. That’s because the convergence of DNA editing, artificial intelligence, and gene therapies, importantly CRISPR gene editing, is going to cure disease,” as quoted by The Motley Fool.
Even more impressive, according to Interesting Engineering, “researchers have already identified DNA errors as the cause of nearly 7,000 diseases. Thankfully, the growing world of genome editing could be the ‘spell-checker’ needed to detect and eventually fix these.”
Some of the top gene editing stocks to keep an eye on include Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and CRISPR Therapeutics (CRSP).